BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 20 filers reported holding BIOXCEL THERAPEUTICS INC in Q2 2018. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $1,027,000 | -17.8% | 23,800 | -12.0% | 0.00% | 0.0% |
| Q4 2020 | $1,249,000 | +5.5% | 27,037 | -1.0% | 0.00% | 0.0% |
| Q3 2020 | $1,184,000 | -7.6% | 27,305 | +12.9% | 0.00% | 0.0% |
| Q2 2020 | $1,282,000 | -44.6% | 24,182 | -76.6% | 0.00% | -66.7% |
| Q1 2020 | $2,314,000 | -49.8% | 103,535 | -67.2% | 0.00% | -25.0% |
| Q4 2019 | $4,612,000 | +107.5% | 315,700 | 0.0% | 0.00% | +100.0% |
| Q3 2019 | $2,223,000 | -32.0% | 315,700 | +5.8% | 0.00% | -50.0% |
| Q2 2019 | $3,270,000 | +10.8% | 298,400 | 0.0% | 0.00% | 0.0% |
| Q1 2019 | $2,951,000 | +156.2% | 298,400 | 0.0% | 0.00% | +100.0% |
| Q4 2018 | $1,152,000 | -49.6% | 298,400 | 0.0% | 0.00% | -33.3% |
| Q3 2018 | $2,286,000 | -16.7% | 298,400 | 0.0% | 0.00% | -25.0% |
| Q2 2018 | $2,745,000 | -18.4% | 298,400 | -9.1% | 0.00% | -20.0% |
| Q1 2018 | $3,362,000 | – | 328,300 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 550,000 | $23,848,000 | 3.05% |
| SPHERA FUNDS MANAGEMENT LTD. | 269,300 | $11,677,000 | 1.15% |
| Avidity Partners Management LP | 538,000 | $23,328,000 | 1.08% |
| Knoll Capital Management, LLC | 20,000 | $867,000 | 0.71% |
| Maven Securities LTD | 200,000 | $8,610,000 | 0.71% |
| Prosight Management, LP | 29,800 | $1,292,000 | 0.62% |
| Artemis Investment Management LLP | 1,001,708 | $43,383,000 | 0.54% |
| Ikarian Capital, LLC | 150,000 | $6,504,000 | 0.47% |
| AlphaCentric Advisors LLC | 20,000 | $867,000 | 0.42% |
| MOODY ALDRICH PARTNERS LLC | 19,872 | $862,000 | 0.18% |